E. coli High-Yield Cell-Free Protein Expression Kit

Built for diverse needs and high‑performance workflows, this cell-free protein expression kit leverages the Continuous Exchange Cell-Free (CECF) principle along with an enhanced E.coli lysate to achieve medium-to-preparative-scale protein yields from plasmid DNA. It supports efficient and scalable production of up to 6-mg protein per run.

E. coli Cell-Free Protein Expression Kit

Go from genes to proteins in hours. This fast cell‑free protein synthesis system uses optimized E. coli lysates and supports both circular and linear DNA templates to produces up to 20 µg of functional protein in 4 hours. Ideal for rapid screening, parallel expression, and workflow scaling in tubes or microplates.

SpCas9 Guide RNA Control

This validated controls kit is engineered for SpCas9 gene editing in human cells. It enables the precise assessment of cleavage efficiency and specificity by providing benchmark positive and negative gRNAs targeting a known locus. These controls are essential for optimizing transfection or electroporation protocols, validating sgRNA delivery, and quantifying on-target indel formation for reliable data normalization.

hfCas12MAX gRNA, mod, 200 nmol, Tube

hfCas12MAX gRNA, mod, 100 nmol, Tube

hfCas12MAX gRNA, mod, 50 nmol, Tube

hfCas12MAX gRNA, mod, 30 nmol, Tube

hfCas12MAX gRNA, mod, 20 nmol, Tube

eSpOT-ON Recombinant Protein

eSpOT-ON nuclease is an engineered high-fidelity Cas9 protein designed for therapeutic applications. It offers high on-target editing efficiency while minimizing off-target activity, making it a safer choice for precise cell and gene therapy development. This Cas9 protein is optimized for both accuracy and safety, providing a reliable solution for your gene editing needs.

eSpOT-ON mRNA

eSpOT-ON is an engineered high-fidelity Cas9 variant, designed for therapeutic gene editing. Delivered in mRNA format, eSpOT-ON provides superior on-target activity with low off-target effects. This nuclease has been validated in preclinical studies and is ready to support your next breakthrough in cell and gene therapy development.